Nanomedicine in the treatment of Glioblastoma

Syeda Kubra Kishwar Jafri, Syed Sarmad Bukhari, Muhammad Shahzad Shamim

Research output: Contribution to journalArticlepeer-review


The current standard of care in glioblastoma management is surgery followed by chemotherapy and radiotherapy. Temozolomide is an alkylating agent most commonly used with a few other second line options. The efficacy of systemic chemotherapy in brain malignancies is limited due to the nature of the blood-brain barrier. Nanomedicine offers one avenue of improving drug delivery to these tumours in a more focussed and effective way in higher doses than currently possible, while simultaneously reducing systemic toxicity.

Original languageEnglish
Pages (from-to)2678
Number of pages1
JournalJPMA. The Journal of the Pakistan Medical Association
Issue number11
Publication statusPublished - 1 Nov 2021


  • Glioblastoma multiforme, brain tumour, nanotechnology


Dive into the research topics of 'Nanomedicine in the treatment of Glioblastoma'. Together they form a unique fingerprint.

Cite this